Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs). SUBTITLE: Amendment to Include Switches From Additional Antiretroviral Regimens

Next Previous
Trial Profile

A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs). SUBTITLE: Amendment to Include Switches From Additional Antiretroviral Regimens

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doravirine/lamivudine/tenofovir disoproxil fumarate (Primary) ; Abacavir; Atazanavir; Cobicistat; Darunavir; Efavirenz; Elvitegravir; Lopinavir; Nevirapine; Rilpivirine; Ritonavir
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms DRIVE-SHIFT
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 18 Sep 2024 This trial has been completed in Spain (End date: 2023-09-05) according to European Clinical Trials Database record.
  • 13 Sep 2023 Status changed from active, no longer recruiting to completed.
  • 26 Oct 2022 Results (of three phase 3 studies DRIVE-FORWARD, DRIVE- AHEAD and DRIVE-SHIFT) assessing Factors associated with weight loss or stable weight after continuing or switching to a doravirine-based regimen presented at the 16th International Congress on Drug Therapy and HIV Infection

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top